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Abstract
Background: Although CT colonography is a less invasive alternative for colonoscopy for the detection of
colorectal polyps and cancer, procedural pain is common. In several studies, CT colonography pain and burden is
higher than in colonoscopy. Apart from discomfort, anxiety and its related stress-induced peri- procedural side
effects, this may influence the adherence for CT colonography as a possible screening tool for colorectal cancer.
We hypothesize that a single bolus intravenous alfentanil will give a clinically relevant reduction in maximum pain
defined as at least 1.3 point reduction on an 11-point numeric rating scale (NRS).
Methods/Design: A randomized double-blind placebo-controlled trial in which patients scheduled for elective CT
colonography in a single tertiary centre are eligible for inclusion. The first 90 consenting patient will be block-
randomized to either the alfentanil group or the placebo group. Before bowel insufflation, the alfentanil group
receives a single bolus intravenous alfentanil 7.5 μg/kg dissolved in 0.9% NaCl, while the placebo group receives an
intravenous bolus injection of pure 0.9% NaCl. For both groups an equal amount of fluid per kilogram (75 μL/kg) is
injected. The primary outcome is the difference in maximum pain on an 11-point NRS. Secondary outcomes
include: pain and burden of different CT colonography aspects, side effects, procedural time and recovery time. For
the primary outcome an independent samples t-test is performed and a P value < 0.05 is considered statistically
significant.
Discussion: This study will provide evidence whether a single bolus intravenous alfentanil gives a clinically relevant
reduction in maximum pain during CT colonography.
Trial registration: Netherlands Trial Register (NTR): NTR2902
This trial will be conducted in accordance with the protocol and in compliance with the moral, ethical, and scientific
principles governing clinical research as set out in the Declaration of Helsinki (1989) and Good Clinical Practice (GCP).
The department of radiology of the Academic Medical Center of Amsterdam is responsible for the design and conduct
of the trial.
Background
Computed tomographic (CT) colonography is an equally
accurate and less invasive alternative for colonoscopy for
diagnosing colorectal cancers and large- to medium-sized
polyps [1-3]. The method is used in clinical practice while
it has been adopted as colorectal cancer screening tool in
the USA and is being considered as such in other coun-
tries [4,5]. Although CT colonography is less invasive than
colonoscopy, pain is frequently observed during bowel
insufflation [6-12]. Insufflation is a prerequisite for accu-
rate visualization of the bowel wall [13]. Bowel insufflation
causes stretching of the bowel and may result in colonic
cramp which causes pain. In some studies pain and/or
burden of CT colonography even compares unfavourably
with conventional colonoscopy under conscious sedation
[6-8].
Apart from the discomfort, anxiety and its related
stress-induced side effects peri- procedural the, the
experienced pain may well reduce the adherence of CT
colonography as a potential screening tool for colorectal
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majority of participants does not benefit from the scan -
participants will give a substantial weight to pain and
burden compared with symptomatic patients who are
much more likely to benefit from the scan.
During conventional colonoscopy administration of
analgesics is standard. To the best of our knowledge, no
analgesic is administered during CT colonography. To
induce sufficient analgesia during CT colonography an
opioid will be necessary. Studies using preventive oral
analgesic agents for acute pain often do not result in a sig-
nificant pain reduction [14-17]. In colonoscopy opioids are
routinely used, often in combination with a benzodiaze-
pine because of the synergetic effect [18,19]. CT colono-
graphy is expected to be less painful compared with
colonoscopy without the administration of analgesic medi-
cation. A benzodiazepine as co-medication is therefore
probably not required. Because of a procedural time of
about 20 minutes a short acting opioid like fentanyl or
alfentanil will be sufficient and thus prevents long recovery
times [20-22]. An opioid bolus has been shown to improve
pain scores during sigmoidoscopy [23]. Alfentanil has the
advantage of being one of the most short-acting opioids
and with the shortest recovery time [20-22]. The need for
recovery facilities could have detrimental consequences on
the clinical use as well as for CT colonography as a screen-
ing tool and this favours alfentanil [24].
Alfentanil is a relatively safe drug, but has possible side
effects like other opioids such as: nausea, vomiting, hypo-
tension, bradycardia and respiratory depression. How-
ever, in low- to medium-dose and without the use of a
benzodiazepine, the incidence respiratory depression is
extremely low [20,22,25,26]. In a study of Cho et al. a
bolus injection of 10 μg/kg alfentanil did not induce any
hypoxemia, desaturations or apnoeas [26].
Before considering analgesia in CT colonography, clini-
cally relevant pain reduction, burden and acceptance,
without detrimental effects on safety and cost-effectiveness
should be demonstrated. For assessment of pain during a
procedure, a numeric rating scale (NRS) is often used
instead of a visual analogue scale (VAS), because it can be
assessed verbally. We have experience with an 11-point
NRS for pain assessment during our CT colonography
procedure and therefore these data can serve as pilot data.
A reduction of 1.3 points on an 11-point NRS is consid-
ered the minimum clinically relevant pain reduction
[27-29]. To evaluate the effect of an intervention with
medication such as alfentanil in CT colonography, a ran-
domized (placebo) controlled trials is the optimal study
design. As alfentanil is dissolved in a 0.9% saline solution,
an ideal placebo would be 0.9% saline, above all because
the colour and viscosity is similar.
We therefore perform a randomized double-blind pla-
cebo-controlled trial to evaluate the effect of a single
bolus intravenous alfentanil of 7.5 μg/kg on the pain
during CT colonography. We hypothesize that a single
bolus intravenous alfentanil will give a clinically relevant
reduction in maximum pain defined as at least 1.3 point
r e d u c t i o no na n1 1 - p o i n tN R S .T ot h eb e s to fo u r
knowledge no previous study evaluated the use of
analgesia in CT colonography.
Methods/Design
Objectives
Primary objective
To evaluate whether a single intravenous alfentanil bolus
(7.5 μg/kg) has a clinically relevant analgesic effect in
patients undergoing elective CT colonography compared
with placebo. We have defined a clinically relevant effect
as a pain reduction of 1.3 point on an 11-point NRS
[27,29].
Secondary objectives
To assess the difference in:
￿ Pain score in all insufflation positions (right and
left decubitus, supine and prone) and the average
pain score
￿ Pain and burden of all CT colonography aspects
(bowel preparation with oral iodinated contrast and
diet, cannula insertion, rectal catheter insertion,
insufflation, positional change on table and period
after the procedure), and total pain and burden of
CT colonography
￿ Side effects of alfentanil during CT colonography
including:
○ respiratory effects (apnoea, respiratory fre-
quency, and blood oxygenation)
○ hemodynamics (heart rate and blood pressure)
￿ Procedure and recovery time
￿ T h em o s tp a i n f u la n dm o s tb u r d e n s o m ea s p e c to f
CT colonography
Trial design
This study will be a single-centre randomized double-
blind placebo-controlled trial.
Population
Consecutive 90 patients between 18 and 85 years from
the Academic Medical Center (AMC) of the University
of Amsterdam, who give informed consent, will be
included. The population in the AMC scheduled for CT
colonography is a mixed group of sexes, ethnic back-
grounds, and mostly elderly patients.
Exclusion criteria
￿ Hypotension (systolic blood pressure < 90 mmHg)
￿ Bradycardia (heart rate < 50 beats per minute)
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￿ Known allergy for alfentanil
￿ Pregnancy (if the patient indicates any chance of
being pregnant, this will be tested)
￿ Known severe liver disease defined as a Child-Pugh
score of > 4
￿ Use of MAO-inhibitors or within two weeks before
the CT colonography procedure
￿ Use of barbiturates, opiates or daily benzodiazepine
use
￿ Known increased intracranial pressure
The number of excluded patients and the reasons for
their exclusion will be recorded and also reported in the
following article.
Sample size
The sample size calculation was aimed at the detection of
a difference in pain score between the alfentanil and pla-
cebo group. We calculated average pain score and stan-
dard deviation of a population screening trial performed
in the AMC where the same insufflation procedure and
11-point NRS were used. The standard deviation was 2.6
in the pilot data. Based on our clinical experience with
alfentanil we assume alfentanil will cause a reduction of
1.5 on an 11-point NRS. We tested this with a one-sided
test, using 0.05 significance and 80% power. An indepen-
dent samples t-test to compare means in two groups in
nQuery Advisor 7.0, results in groups of 38 subjects. With
an anticipated withdrawal rate of approximately 5%, we
aim to include 45 patients per group.
Informed consent
Patients scheduled for an elective CT colonography proce-
dure will be asked by telephone to participate [Figure 1].
The exclusion criteria will be checked during this conver-
sation and if they are eligible for inclusion and interested
in participating in our study, the patient information will
be sent. Patients are included after written informed con-
sent. Patients may decide to participate in our study until
two days before CT colonography.
Intervention
Subjects randomized to group 1 will receive alfentanil
(Rapifen, Janssen-Cilag, Tilburg, the Netherlands) 7.5 μg/kg
intravenously through a 20 Gauge intravenous cannula.
Subjects randomized to group 2 will receive a placebo, in
this study a 0.9% saline solution 75 μL/kg through a 20
Gauge intravenous cannula. For both groups an equal
amount of fluid (75 μL/kg) will be injected. This placebo is
chosen because alfentanil is dissolved in 0.9% saline solu-
tion. After administration of the spasmolytic agent the line
is flushed with 5 mL 0.9% and again after administration of
the study medication. Both the physician performing the
CT colonography scans as well as the patient are blinded to
the allocated group. Oxygen saturation, heart rate, and
blood pressure will be measured during the CT colonogra-
phy procedure, using a pulse oximeter and automated
blood pressure monitor. A pain evaluation will be per-
formed during insufflation in left decubitus, right decubitus,
supine and prone position (see section pain evaluation).
Two questionnaires with 22 and 17 questions, mostly
multiple-choice, will be given during this study: the first
before randomization and the second after completion
of CT colonography.
CT colonography
Both preparation and insufflation are performed as used in
current clinical practice in our institution. The preparation
for CT colonography consists of two bottles of 50 mL iodi-
nated contrast, meglumine ioxithalamate (Telebrix, Guer-
bet, Aulnay sous Bois, France), the day before and one
bottle in the morning of CT colonography and a low-fibre
diet for these days [30]. Colonic distension will be obtained
by the automated administration of carbon dioxide (PRO-
TOCO2L, Bracco, EZEM, Lake Success, USA) through a
flexible 20 French rectal tube after intravenous administra-
tion of 1 mL (20 mg) butylscopalamine bromide (Busco-
pan, Boehringer-Ingelheim, Ingelheim, Germany) or, if
contraindicated 1 mL (1 mg), Glucagon (GlucaGen, Novo
Nordisk A’S, Bagsvaerd, Denmark). Insufflation takes place
in three positions: right decubitus, left decubitus, and
supine position. The aim is to insufflate three litres of car-
bon dioxide with 1.3, 0.9, and 0.8 litres per position,
respectively. After five minutes the insufflation is stopped,
whether the target of three litres is reached or not. The
scan is performed using a 64-slice CT scanner (Brilliance,
Philips Medical Systems, Best, the Netherlands) using dose
modulation. A scan is performed in both supine and prone
position. In case of clinical suspicion of colorectal cancer,
100 mL intravenous iodinated contrast agent, iopromide
(Ultravist 300, Bayer B.V., Mijdrecht, the Netherlands) will
be administered in supine position. Otherwise both series
are unenhanced.
Parameter unenhanced CT: 120 kV
40 reference mAs
64 × 0.625 collimation
0.9 mm slice thickness
Parameters contrast-enhanced CT: 120 kV
200 or 250 reference mAs
64 × 0.625 collimation
0.9 mm slice thickness
Analgesia
One of the two independent research physicians, who
are in control of the randomization list, will prepare the
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fied physician, who performs the CT colonography, will
infuse the medication/placebo via the intravenous can-
nula over a period of approximately two minutes. The
medication/placebo is given 1.5 minutes after butyl sco-
polamine or glucagon is given and the average blood
pressure and heart rate has been recorded. Butyl scopo-
lamine influences the heart rate and blood pressure.
After 1.5 minutes the effect of butyl scopolamine on the
heart rate and blood pressure is present and a reliable
baseline value can be registered.
Monitoring
During the whole procedure, the patients will be moni-
tored using a pulse oximeter. An automatic blood pressure
device will monitor the blood pressure before administra-
tion of the spasmolytic agent and 1.5 minutes after the
spasmolytic agent is given intravenously. After the first
blood pressure measurement the blood pressure is auto-
matically measured and recorded every five minutes. The
heart rate and oxygen saturation is continuously recorded
by pulse oximetry.
Pain evaluation
During the procedure pain is assessed immediately after
insufflation in left decubitus, right decubitus, supine and
after scanning in prone position using an 11-point NRS.
This score starts at 0, meaning no pain at all and ends at
10 means the worst pain imaginable. The score therefore
contains 11 points. All four pain scores will be reported.
Figure 1 Flow chart according to the CONSORT statement 2010.
Boellaard et al. BMC Gastroenterology 2011, 11:128
http://www.biomedcentral.com/1471-230X/11/128
Page 4 of 8Time
The begin time and end time of the CT colonography pro-
cedure will be noted. The begin time is defined as the
moment the patient enters the CT scanner room after
changing clothes. The end time is defined as the moment
the patient leaves the CT scanner room after the CT scan
has been performed. Additionally, the time from the start
of the procedure until the end time of recovery is noted.
The end of recovery is defined as the time that the first
Aldrete score of 9 or higher is measured.
Questionnaires
All patients scheduled for clinical CT colonography will
receive patient information and an informed consent
form. Along with these forms, a pre-procedural ques-
tionnaire is sent to assess the baseline characteristics
and expectations:
￿ Baseline characteristics include: age, gender, mari-
tal status, ethnicity, and education
￿ Expectations include burden and pain of: the bowel
preparation, intravenous cannula insertion, bowel
insufflation, and the total procedure on a standard
formatted 5-point scale (no pain, mild pain, moder-
ate pain, severe pain, and very severe pain)
A post-procedural questionnaire is given 30 minutes
after the procedure. This time is standardized because
t h et i m eb e t w e e nt h ep r o c e d u r ea n dt h eq u e s t i o n n a i r e
may influence the answers. This questionnaire is
designed to assess the experienced burden and accept-
ability:
￿ Experience includes burden and pain of: the bowel
preparation, intravenous cannula insertion, bowel
insufflation, and the total procedure on standard for-
matted 5-point scale (identical to the pre-procedural
form)
￿ Which aspect of the procedure was most painful or
burdensome (bowel preparation, intravenous cannula
insertion, rectal catheter insertion, bowel insufflation,
turning on the examination table or symptoms after
examination)
￿ Acceptance includes: if they would accept this as a
method for population screening
Both the pre-procedural questionnaire and post-proce-
dural questionnaire are based on questionnaires used in
a previous CT colonography trial [4].
Adverse events
Serious adverse event as defined by the ICH Guidelines
for Good Clinical Practice E6 will be recorded and
reported and mild adverse events, such as nausea will be
recorded.
Safety
An oxygen mask, an AMBU set, and naloxone will be
available on site. The research physician, who prepares
the study medication, will leave a signed sealed envelope
(with patient name and patient number) with the given
medication, which can be opened in case a serious
adverse event occurs. The most serious adverse event
caused by alfentanil within this setting is respiratory
depression. The person administering alfentanil is trained
in advanced life support; ensuring that this individual is
competent in diagnosing respiratory depression and per-
forming the appropriate treatment. In case of respiratory
depression the patient will be ventilated, using a bagging
bag with mask. Therefore oxygen, mask, and a bagging
bag will be nearby.
To antagonize the induced respiratory depression 0.2-
0.4 mg naloxone (B. Braun, Melsungen, Germany) will be
given if necessary and can be repeated every 2-3 minutes.
As extra precaution, a rescue plan has been created
describing all steps that need to be performed in case of
respiratory depression, hypotension, and bradycardia. The
anaesthesiologists on call for emergency situations are
informed about all CT colonography exams that will be
performed.
Recovery criteria
Each patient has to be observed by a blinded qualified staff
member for one hour after the CT colonography proce-
dure. For the monitoring of the recovery, the Aldrete score
[31], a very commonly used score for recovery monitoring,
is used at arrival at the recovery room and at 30 min and
60 min after alfentanil administration [Figure 2]. A score of
9 or higher obtained at 60 minutes is considered as ready
for discharge and the participant may go home. If the score
is lower than 9, another Aldrete score will be performed at
90 and 120 minutes. All scores will be recorded.
Statistical analysis
SPSS version 16.0 is used for all statistical calculations.
A P value of 0.05 is defined as significant. Baseline char-
acteristics are summarized with descriptive statistics. For
categorical data the numbers or proportions are given,
for normal distributed data the mean and standard
deviation and for not normal distributed data the med-
ian with percentiles.
Differences between the alfentanil group and the pla-
cebo group will be tested for significance. For the calcu-
lation of differences in pain scores per position, average,
and the maximum pain score during the procedure will
be calculated using an independent samples t-test.
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cedure as well as the total procedural burden will be
calculated using a chi-square test. Differences in the
most burdensome aspect will also be calculated using
the chi-square test. Differences in procedural time and
recovery time will be calculated using an independent
samples t-test.
We will test the associations between the baseline
characteristics (independent variables mentioned below)
and pain scores. As we consider the pain scores as con-
tinuous data, for this approach we will perform linear
regression analyses.
Univariate analyses will be performed with pain scores
as dependent variable and the following variables as
independent variables: age, sex, BMI, education, ethni-
city, expected burden, scan indication (including abdom-
inal pain), known diseases and diagnosis, and whether it
is the first CT colonography. Subsequently, the variables
with a P value < 0.1 will be included in the multivariate
analysis. In case more than four variables turn out to
result in a P < 0.1, the four most influential variables
will be used in the multivariate analysis. A stepwise
backward selection strategy will be used, with a P value
< 0.05 considered statistically significant.
Ethical approval
Ethical approval was obtained from the Medical Ethics
Committee of the Academic Medical Center, Amster-
dam, the Netherland (NL35916.018.11). A marginal
review was performed by the National Authority, the
Central Committee on Research Involving Human Sub-
jects (CCMO), and there were no objections to perform
this study (NL35916.018.11 BI).
Discussion
CT colonography is a structural examination of the
colon and rectum. It is used in high risk patients as an
alternative for colonoscopy or in case colonoscopy is
Aldrete score:
  »Motoric activity
Spontaneous movement when addressed      2
Weak spontaneous movements when addressed     1
No  movement       0
  »Breathing
Coughs on comment or cries         2
Keeps the airway open           1
Obstructed  airways        0
  »Blood pressure compared to reference measurement*
̇  <  20  mm  Hg       2
̇ = 20 – 50 mm Hg          1
̇ > 50 mm Hg             0
  »Consciousness
Awake        2
Response to stimulus, reflexes intact       1
No answer, reflexes absent          0
  »Oxygen saturation 
100  -  98  %         2
97  -  95  %         1
<  95  %          0
*Reference measurement is performed 1½ minutes after 
administration of the spasmolytic agent.
Figure 2 Aldrete recovery criteria.
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phy is less invasive, results on pain and burden during
these examinations in literature are variable. Several stu-
dies show higher procedural pain and burden for CT
colonography compared with colonoscopy with con-
scious sedation due to air or carbon dioxide insufflation
[6-8]. With an appropriate analgesic agent, CT colono-
graphy may not only be less invasive, but also less pain-
ful and less burdensome, which would be advantageous
for patients.
Additionally, the screening test for colorectal cancer is
still under debate. Several screening tools are available
such as faecal occult blood test, sigmoidoscopy, colono-
scopy, and CT colonography. The effectiveness of a
screening tool is influenced by both participation and
yield. Colonoscopy and CT colonography are the most
sensitive techniques for the detection of colorectal neopla-
sia, i.e. colorectal cancer and its precursor, colorectal
advanced adenomas [32]. The advantages of colonoscopy
are the highest sensitivity and opportunity for direct polyp
removal. Advantages of CT colonography are that this
technique is less invasive and has a very low complication
rate [33]. CT colonography adherence and participation
most likely will be influenced by a clinically relevant
reduction in pain and burden experienced during the
examination and therefore may have impact on the princi-
pal outcome measure of colorectal cancer screening, i.e.
the number of advanced neoplasia per 100 invitees.
This RCT will provide evidence whether a single bolus
intravenous alfentanil gives a clinically relevant reduction
in maximum pain during CT colonography. Furthermore,
this study will provide information about the effect of
alfentanil on pain and burden of different CT colonogra-
phy aspects, side effects, adverse events, procedural time
and recovery time. We expect a clinically relevant reduc-
tion of procedural pain and burden without adverse events
and recovery time. This could make CT colonography a
more patient-friendly examination and is likely to increase
participation for its use as a screening tool.
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